SCHEMBL22991233

SCHEMBL22991233

CC(C)C(=O)N1C[C@H]2C[C@H]2C1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 9/20 0.63
CHRNA3 P32297 9/20 0.63
CHRNA4 P43681 9/20 0.63
CHRNB3 Q05901 2/20 0.63
CHRNA6 Q15825 2/20 0.63
PIK3CD O00329 1/20 0.42
DPP4 P27487 1/20 0.40
CHRNB4 P30926 7/20 0.35
JAK1 P23458 3/20 0.34
JAK2 O60674 2/20 0.34
JAK3 P52333 2/20 0.34
CHRNA7 P36544 5/20 0.34
NR1H2 P55055 1/20 0.34
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16219020 1.00 CHRNB2 (0.63) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL18348009 0.89 CHRNB2 (0.57) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL18498298 0.82 CHRNB2 (0.53) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL18347964 0.82 CHRNB2 (0.53) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL24869655 0.82 CHRNB2 (0.53) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL18347986 0.82 CHRNB2 (0.53) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL18517354 0.82 CHRNB2 (0.53) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL18348011 0.82 CHRNB2 (0.53) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL12308335 0.82 CHRNB2 (0.53) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL14453854 0.80 CHRNB2 (0.52) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240217990-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. 2024-07-04 US disclosed
US-11718628-B2 SREBP inhibitors comprising a 6-membered central ring CAPULUS THERAPEUTICS, LLC (US) 2023-08-08 US disclosed
US-20210047340-A1 SREBP INHIBITORS COMPRISING A 6-MEMBERED CENTRAL RING CAPULUS THERAPEUTICS, LLC 2021-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718628-B2 SREBP inhibitors comprising a 6-membered central ring SREBF1, SREBF2, XBP1 CHRNB2 4658/4885CHRNA3 4612/4885CHRNA4 4783/4885
US-20210047340-A1 SREBP INHIBITORS COMPRISING A 6-MEMBERED CENTRAL RING SREBF1, SREBF2, XBP1 CHRNB2 4658/4885CHRNA3 4612/4885CHRNA4 4783/4885
US-20240217990-A1 THIENOPYRROLE COMPOUNDS SSB, TPMT, LCP2 CHRNB2 4832/4885CHRNA3 4571/4885CHRNA4 4756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.